Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy - PubMed
4 hours ago
- #Alzheimer's disease
- #amyloid positivity
- #real-world study
- Confirmatory biomarker testing for Alzheimer's disease in Japan is insurance-covered only when assessing eligibility for anti-amyloid-β therapies.
- This real-world study aimed to identify clinical and MRI features associated with amyloid positivity in patients undergoing secondary screening.
- Younger age and lower Mini-Mental State Examination (MMSE) scores were linked to amyloid positivity, despite similar symptom duration.
- MRI features mostly overlapped between groups, except for a higher medial-temporal-whole-brain atrophy ratio in the amyloid-positive group.
- The findings suggest caution is needed regarding referral bias for early-onset Alzheimer's disease in clinical practice.